Identification of a splicing variant that regulates type 2 diabetes risk factor CDKAL1 level by a coding-independent mechanism in human

Bo Zhou, Fan Yan Wei, Narumi Kanai, Atsushi Fujimura, Taku Kaitsuka, Kazuhito Tomizawa

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Single-nucleotide polymorphisms (SNPs) in CDKAL1 have been associated with the development of type 2 diabetes (T2D). CDKAL1 catalyzes 2-methylthio modification of adenosine at position 37 of tRNALys(UUU). Adeficit of this modification causes aberrant protein synthesis, and is associated with impairment of insulin secretion in both mouse model and human. However, it is unknown whether the T2D-associated SNPs in CDKAL1 are associated with downregulation of CDKAL1 by regulating the gene expression. Here, we report a specific splicing variant of CDKAL1 termed CDKAL1-v1 that is markedly lower in individuals carrying risk SNPs of CDKAL1. Interestingly, CDKAL1-v1 is a non-coding transcript, which regulates the CDKAL1 level by competitive binding to a CDKAL1-targeting miRNA. By direct editing of the genome, we further show that the nucleotides around the SNPregions are critical for the alternative splicing of CDKAL1-v1. These findings reveal that the T2D-associated SNPs inCDKAL1 reduce CDKAL1-v1 levels by impairing splicing, which in turn increasesmiRNA-mediated suppression ofCDKAL1. Our results suggest that CDKAL1-v1-mediated suppression ofCDKAL1 might underlie the pathogenesis of T2D in individuals carrying the risk SNPs.

Original languageEnglish
Article numberddu184
Pages (from-to)4639-4650
Number of pages12
JournalHuman Molecular Genetics
Volume23
Issue number17
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Single Nucleotide Polymorphism
RNA, Transfer, Lys
Competitive Binding
Alternative Splicing
MicroRNAs
Down-Regulation
Nucleotides
Insulin
Gene Expression
Proteins

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology
  • Medicine(all)

Cite this

Identification of a splicing variant that regulates type 2 diabetes risk factor CDKAL1 level by a coding-independent mechanism in human. / Zhou, Bo; Wei, Fan Yan; Kanai, Narumi; Fujimura, Atsushi; Kaitsuka, Taku; Tomizawa, Kazuhito.

In: Human Molecular Genetics, Vol. 23, No. 17, ddu184, 2014, p. 4639-4650.

Research output: Contribution to journalArticle

Zhou, Bo ; Wei, Fan Yan ; Kanai, Narumi ; Fujimura, Atsushi ; Kaitsuka, Taku ; Tomizawa, Kazuhito. / Identification of a splicing variant that regulates type 2 diabetes risk factor CDKAL1 level by a coding-independent mechanism in human. In: Human Molecular Genetics. 2014 ; Vol. 23, No. 17. pp. 4639-4650.
@article{83684be53bb240fc927e9100c2bd6236,
title = "Identification of a splicing variant that regulates type 2 diabetes risk factor CDKAL1 level by a coding-independent mechanism in human",
abstract = "Single-nucleotide polymorphisms (SNPs) in CDKAL1 have been associated with the development of type 2 diabetes (T2D). CDKAL1 catalyzes 2-methylthio modification of adenosine at position 37 of tRNALys(UUU). Adeficit of this modification causes aberrant protein synthesis, and is associated with impairment of insulin secretion in both mouse model and human. However, it is unknown whether the T2D-associated SNPs in CDKAL1 are associated with downregulation of CDKAL1 by regulating the gene expression. Here, we report a specific splicing variant of CDKAL1 termed CDKAL1-v1 that is markedly lower in individuals carrying risk SNPs of CDKAL1. Interestingly, CDKAL1-v1 is a non-coding transcript, which regulates the CDKAL1 level by competitive binding to a CDKAL1-targeting miRNA. By direct editing of the genome, we further show that the nucleotides around the SNPregions are critical for the alternative splicing of CDKAL1-v1. These findings reveal that the T2D-associated SNPs inCDKAL1 reduce CDKAL1-v1 levels by impairing splicing, which in turn increasesmiRNA-mediated suppression ofCDKAL1. Our results suggest that CDKAL1-v1-mediated suppression ofCDKAL1 might underlie the pathogenesis of T2D in individuals carrying the risk SNPs.",
author = "Bo Zhou and Wei, {Fan Yan} and Narumi Kanai and Atsushi Fujimura and Taku Kaitsuka and Kazuhito Tomizawa",
year = "2014",
doi = "10.1093/hmg/ddu184",
language = "English",
volume = "23",
pages = "4639--4650",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "17",

}

TY - JOUR

T1 - Identification of a splicing variant that regulates type 2 diabetes risk factor CDKAL1 level by a coding-independent mechanism in human

AU - Zhou, Bo

AU - Wei, Fan Yan

AU - Kanai, Narumi

AU - Fujimura, Atsushi

AU - Kaitsuka, Taku

AU - Tomizawa, Kazuhito

PY - 2014

Y1 - 2014

N2 - Single-nucleotide polymorphisms (SNPs) in CDKAL1 have been associated with the development of type 2 diabetes (T2D). CDKAL1 catalyzes 2-methylthio modification of adenosine at position 37 of tRNALys(UUU). Adeficit of this modification causes aberrant protein synthesis, and is associated with impairment of insulin secretion in both mouse model and human. However, it is unknown whether the T2D-associated SNPs in CDKAL1 are associated with downregulation of CDKAL1 by regulating the gene expression. Here, we report a specific splicing variant of CDKAL1 termed CDKAL1-v1 that is markedly lower in individuals carrying risk SNPs of CDKAL1. Interestingly, CDKAL1-v1 is a non-coding transcript, which regulates the CDKAL1 level by competitive binding to a CDKAL1-targeting miRNA. By direct editing of the genome, we further show that the nucleotides around the SNPregions are critical for the alternative splicing of CDKAL1-v1. These findings reveal that the T2D-associated SNPs inCDKAL1 reduce CDKAL1-v1 levels by impairing splicing, which in turn increasesmiRNA-mediated suppression ofCDKAL1. Our results suggest that CDKAL1-v1-mediated suppression ofCDKAL1 might underlie the pathogenesis of T2D in individuals carrying the risk SNPs.

AB - Single-nucleotide polymorphisms (SNPs) in CDKAL1 have been associated with the development of type 2 diabetes (T2D). CDKAL1 catalyzes 2-methylthio modification of adenosine at position 37 of tRNALys(UUU). Adeficit of this modification causes aberrant protein synthesis, and is associated with impairment of insulin secretion in both mouse model and human. However, it is unknown whether the T2D-associated SNPs in CDKAL1 are associated with downregulation of CDKAL1 by regulating the gene expression. Here, we report a specific splicing variant of CDKAL1 termed CDKAL1-v1 that is markedly lower in individuals carrying risk SNPs of CDKAL1. Interestingly, CDKAL1-v1 is a non-coding transcript, which regulates the CDKAL1 level by competitive binding to a CDKAL1-targeting miRNA. By direct editing of the genome, we further show that the nucleotides around the SNPregions are critical for the alternative splicing of CDKAL1-v1. These findings reveal that the T2D-associated SNPs inCDKAL1 reduce CDKAL1-v1 levels by impairing splicing, which in turn increasesmiRNA-mediated suppression ofCDKAL1. Our results suggest that CDKAL1-v1-mediated suppression ofCDKAL1 might underlie the pathogenesis of T2D in individuals carrying the risk SNPs.

UR - http://www.scopus.com/inward/record.url?scp=84905668914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905668914&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddu184

DO - 10.1093/hmg/ddu184

M3 - Article

C2 - 24760768

AN - SCOPUS:84905668914

VL - 23

SP - 4639

EP - 4650

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 17

M1 - ddu184

ER -